Sema4 Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Virtual Cloud Technologies

The Beachbody Co.

Ontrak

VirnetX

US crude oil futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

5 Stocks Under $2 Insiders Are Aggressively Buying

Sema4 Holdings Corp. (NASDAQ:SMFR ) Q1 2022 Earnings Conference Call May 13, 2022 4:30 PM ET Company Representatives Katherine Stueland - Chief Executive Officer Eric Schadt - Founder, President and Chief R&D Officer Isaac Ro - Chief Financial Officer Joel Kaufman - Vice President of Finance and Corporate Development Conference Call Participants Mark Massaro - BTIG Max Masucci - Cowen and Company Dave Delahunt - Goldman Sachs Operator Good day! And thank you for standing by.

Sema4 Holdings Corp. (SMFR) CEO Katherine Stueland on Q1 2022 Results - Earnings Call Transcript

STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the compensation committee of Sema4's board of directors granted newly-hired employees inducement stock options to purchase an aggregate of 4,932,132 shares of Sema4's Class A common stock (“Class A common stock”) and 4,285,208 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with Sema4. The foregoing includes inducement stock options to purchase an aggregate of 3,551,136 shares of Class A common stock and 2,045,454 restricted stock units granted to Katherine Stueland as an inducement material to the employment of Ms. Stueland as the Chief Executive Officer of Sema4. The stock options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S.

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the first quarter of 2022 after the market close on Thursday, May 12, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET.

Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript

37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year

Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of GeneDx, Inc. to Sema4 Holdings Corp. (“the Company”) (NasdaqGS: SMFR). Under the terms of the proposed transaction, Sema4 will acquire GeneDx for a total upfront consideration of approximately $473 million, and a total aggregate consideration including potential milestones of approximately $623 million, based on the closing stock price of Sema4 as of January 14, 2022. Kuznicki Law is seeking to determine

SEMA4 HOLDINGS INVESTOR ALERT - Kuznicki Law PLLC Investigates Sema4 Holdings Corp. - SMFR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GeneDx, Inc. to Sema4 Holdings Corp. (“the Company”) (NasdaqGS: SMFR). Under the terms of the proposed transaction, Sema4 will acquire GeneDx for a total upfront consideration of approximately $473 million, and a total aggregate consideration including potential milestones of approximately $623 million, based

SEMA4 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Sema4 Holdings Corp. - SMFR

Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2022) - Investor protection firm Kaskela Law LLC announces that is investigating the Board of Directors of Sema4 Holdings Corp. ("Sema4") (NASDAQ: SMFR) on behalf of the company's stockholders.On January 18, 2022, Sema4 announced that it had entered into a definitive agreement to acquire OPKO Health's wholly owned subsidiary, GeneDx, Inc. Under the terms of the proposed transaction, Sema4 is expected to pay $150 million, and issue 80...

INVESTIGATION ALERT: Kaskela Law LLC Announces Stockholder Investigation of Sema4 Holdings Corp. (SMFR) in Connection with Recent Merger Announcement

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Additionally, Company management will participate in two virtual investor conferences in March.

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022

STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences:

Sema4 to Participate at Two Upcoming Investor Conferences in February

30-year industry veteran, Jerry Conway, joins Sema4 as Senior Vice President of Market Access to lead the team 30-year industry veteran, Jerry Conway, joins Sema4 as Senior Vice President of Market Access to lead the team

Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Sema4 Holdings Corp. (NASDAQ: SMFR) and GeneDx, Inc. is fair to Sema4 shareholders. Halper Sadeh encourages Sema4 shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Sema4 and its board violated the federal

Sema4 (SMFR) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Sema4 Holdings Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SMFR

Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623 million. Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years.

Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition

Business combination projected to deliver $350 million in pro forma 2022 revenue

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

The stock price of Sema4 Holdings Corp (NASDAQ: SMFR) increased by 13.63% in the most recent trading session. This is why it happened.

Sema4 Stock (SMFR): Why The Price Jumped

Fourth quarter and fiscal year results are expected to exceed the high end of guidance for both total revenue and resulted test volume Fourth quarter and fiscal year results are expected to exceed the high end of guidance for both total revenue and resulted test volume

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and Chief Executive Officer, and Isaac Ro, Chief Financial Officer, will participate at the upcoming 40th Annual J.P. Morgan Healthcare Conference, which is taking place virtually. Dr. Schadt and Mr. Ro will deliver a formal presentation on Monday, January 10th, 2022 at 4:30 p.m. ET. They will also be available for one-on-ones that same day.

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

Sema4 Holdings Corp (NASDAQ: SMFR) reported Q3 revenues of $43.2 million, +12% Y/Y, beating the consensus of $42.68 million. Diagnostic test revenue was $41.4 million, up 7%, while other revenue more than doubled to $1.8 million.

Sema4, Excluding COVID-19, Posts 36% Increase In Test Volume In Q3

Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q3 2021 Results - Earnings Call Transcript

36% increase in test volume (excluding COVID-19 tests) compared to the same period last year

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences:

Sema4 to Participate at Three Upcoming Investor Conferences in November

STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the third quarter of 2021 after the market close on Monday, November 15, 2021. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET.

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

STAMFORD, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, Ph.D., Founder and Chief Executive Officer, and Isaac Ro, Chief Financial Officer will participate at the following virtual investor conferences:

News for Sema4 Holdings Corp Stock (SMFR)